Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma

Scot C. Remick, James J. McSharry, Barbara C. Wolf, Christina G. Blanchard, Allison Y. Eastman, Henry Wagner, Enrico Portuese, Timothy Wighton, Danielle Powell, Tillman Pearce, John Horton, John C. Ruckdeschel

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Purpose: To determine the toxicity, response, and survival rate of orally administered combination chemotherapy in patients with AIDS-related intermediateand high-grade non-Hodgkin's lymphoma. Secondary objectives included prospective quality-of-life assessment and quantitation of cell-associated p24 antigen (p24 Ag) by flow cytometry. Patients and Methods: Eighteen patients with biopsy-proven lymphoma were treated with oral chemotherapy consisting of lomustine (CCNU) 100 mg/m2 on day 1, etoposide 200 mg/m2 on days 1 through 3; cyclophosphamide 100 mg/m2 on days 22 through 31, and procarbazine 100 mg/m2 on days 22 through 31 at 6-week intervals. A variety of clinical assessments were performed: prospective quality-of-life assessment using the Functional Living Index-Cancer (FLIC) and Brief Symptom Inventory (BSI) instruments; indirect immunofluorescence with flow cytometry to measure cell-associated p24 antigen; and price of the oral regimen compared with two other intravenous combination chemotherapy regimens. Results: The overall objective response rate using Eastern Cooperative Oncology Group (ECOG) criteria was 61 % (95% confidence interval, 39% to 84%), with seven complete remissions (39%) and four partial remissions (22%). The median survival duration was 7 months, with a range of 11 days to 36 months. The treatment-related mortality rate was 11 %. One patient developed CNS progression. Myelosuppression was the most frequent and severe toxicity encountered. Predictor variables of performance status (PS), prior history of thrush, and CD4 lymphocyte count were found to be of prognostic value. In a separate analysis, scores on the three subscales of the BSI were also found to be predictive of complete response. The price of this regimen is several thousand dollars less than that of other intravenous combination chemotherapy regimens. Conclusion: This regimen is active in patients with AIDS-related non-Hodgkin's lymphoma. Because it is important to design systemic cytotoxic chemotherapy regimens that are cost-effective, considerate of quality-of-life issues, and efficacious in this patient population, this approach should be compared with standard intravenous combination chemotherapy regimens in randomized controlled clinical trials.

Original languageEnglish (US)
Pages (from-to)1691-1702
Number of pages12
JournalJournal of Clinical Oncology
Volume11
Issue number9
DOIs
StatePublished - Jan 1 1993

Fingerprint

AIDS-Related Lymphoma
Combination Drug Therapy
Non-Hodgkin's Lymphoma
Quality of Life
Flow Cytometry
Therapeutics
Lomustine
Procarbazine
Oral Candidiasis
Antigens
Drug Therapy
Equipment and Supplies
Etoposide
Indirect Fluorescent Antibody Technique
CD4 Lymphocyte Count
Cyclophosphamide
Lymphoma
Acquired Immunodeficiency Syndrome
Survival Rate
Randomized Controlled Trials

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Remick, Scot C. ; McSharry, James J. ; Wolf, Barbara C. ; Blanchard, Christina G. ; Eastman, Allison Y. ; Wagner, Henry ; Portuese, Enrico ; Wighton, Timothy ; Powell, Danielle ; Pearce, Tillman ; Horton, John ; Ruckdeschel, John C. / Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 9. pp. 1691-1702.
@article{081acc47b6454e31a364e93f113f2c8d,
title = "Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma",
abstract = "Purpose: To determine the toxicity, response, and survival rate of orally administered combination chemotherapy in patients with AIDS-related intermediateand high-grade non-Hodgkin's lymphoma. Secondary objectives included prospective quality-of-life assessment and quantitation of cell-associated p24 antigen (p24 Ag) by flow cytometry. Patients and Methods: Eighteen patients with biopsy-proven lymphoma were treated with oral chemotherapy consisting of lomustine (CCNU) 100 mg/m2 on day 1, etoposide 200 mg/m2 on days 1 through 3; cyclophosphamide 100 mg/m2 on days 22 through 31, and procarbazine 100 mg/m2 on days 22 through 31 at 6-week intervals. A variety of clinical assessments were performed: prospective quality-of-life assessment using the Functional Living Index-Cancer (FLIC) and Brief Symptom Inventory (BSI) instruments; indirect immunofluorescence with flow cytometry to measure cell-associated p24 antigen; and price of the oral regimen compared with two other intravenous combination chemotherapy regimens. Results: The overall objective response rate using Eastern Cooperative Oncology Group (ECOG) criteria was 61 {\%} (95{\%} confidence interval, 39{\%} to 84{\%}), with seven complete remissions (39{\%}) and four partial remissions (22{\%}). The median survival duration was 7 months, with a range of 11 days to 36 months. The treatment-related mortality rate was 11 {\%}. One patient developed CNS progression. Myelosuppression was the most frequent and severe toxicity encountered. Predictor variables of performance status (PS), prior history of thrush, and CD4 lymphocyte count were found to be of prognostic value. In a separate analysis, scores on the three subscales of the BSI were also found to be predictive of complete response. The price of this regimen is several thousand dollars less than that of other intravenous combination chemotherapy regimens. Conclusion: This regimen is active in patients with AIDS-related non-Hodgkin's lymphoma. Because it is important to design systemic cytotoxic chemotherapy regimens that are cost-effective, considerate of quality-of-life issues, and efficacious in this patient population, this approach should be compared with standard intravenous combination chemotherapy regimens in randomized controlled clinical trials.",
author = "Remick, {Scot C.} and McSharry, {James J.} and Wolf, {Barbara C.} and Blanchard, {Christina G.} and Eastman, {Allison Y.} and Henry Wagner and Enrico Portuese and Timothy Wighton and Danielle Powell and Tillman Pearce and John Horton and Ruckdeschel, {John C.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1200/JCO.1993.11.9.1691",
language = "English (US)",
volume = "11",
pages = "1691--1702",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

Remick, SC, McSharry, JJ, Wolf, BC, Blanchard, CG, Eastman, AY, Wagner, H, Portuese, E, Wighton, T, Powell, D, Pearce, T, Horton, J & Ruckdeschel, JC 1993, 'Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma', Journal of Clinical Oncology, vol. 11, no. 9, pp. 1691-1702. https://doi.org/10.1200/JCO.1993.11.9.1691

Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma. / Remick, Scot C.; McSharry, James J.; Wolf, Barbara C.; Blanchard, Christina G.; Eastman, Allison Y.; Wagner, Henry; Portuese, Enrico; Wighton, Timothy; Powell, Danielle; Pearce, Tillman; Horton, John; Ruckdeschel, John C.

In: Journal of Clinical Oncology, Vol. 11, No. 9, 01.01.1993, p. 1691-1702.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma

AU - Remick, Scot C.

AU - McSharry, James J.

AU - Wolf, Barbara C.

AU - Blanchard, Christina G.

AU - Eastman, Allison Y.

AU - Wagner, Henry

AU - Portuese, Enrico

AU - Wighton, Timothy

AU - Powell, Danielle

AU - Pearce, Tillman

AU - Horton, John

AU - Ruckdeschel, John C.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Purpose: To determine the toxicity, response, and survival rate of orally administered combination chemotherapy in patients with AIDS-related intermediateand high-grade non-Hodgkin's lymphoma. Secondary objectives included prospective quality-of-life assessment and quantitation of cell-associated p24 antigen (p24 Ag) by flow cytometry. Patients and Methods: Eighteen patients with biopsy-proven lymphoma were treated with oral chemotherapy consisting of lomustine (CCNU) 100 mg/m2 on day 1, etoposide 200 mg/m2 on days 1 through 3; cyclophosphamide 100 mg/m2 on days 22 through 31, and procarbazine 100 mg/m2 on days 22 through 31 at 6-week intervals. A variety of clinical assessments were performed: prospective quality-of-life assessment using the Functional Living Index-Cancer (FLIC) and Brief Symptom Inventory (BSI) instruments; indirect immunofluorescence with flow cytometry to measure cell-associated p24 antigen; and price of the oral regimen compared with two other intravenous combination chemotherapy regimens. Results: The overall objective response rate using Eastern Cooperative Oncology Group (ECOG) criteria was 61 % (95% confidence interval, 39% to 84%), with seven complete remissions (39%) and four partial remissions (22%). The median survival duration was 7 months, with a range of 11 days to 36 months. The treatment-related mortality rate was 11 %. One patient developed CNS progression. Myelosuppression was the most frequent and severe toxicity encountered. Predictor variables of performance status (PS), prior history of thrush, and CD4 lymphocyte count were found to be of prognostic value. In a separate analysis, scores on the three subscales of the BSI were also found to be predictive of complete response. The price of this regimen is several thousand dollars less than that of other intravenous combination chemotherapy regimens. Conclusion: This regimen is active in patients with AIDS-related non-Hodgkin's lymphoma. Because it is important to design systemic cytotoxic chemotherapy regimens that are cost-effective, considerate of quality-of-life issues, and efficacious in this patient population, this approach should be compared with standard intravenous combination chemotherapy regimens in randomized controlled clinical trials.

AB - Purpose: To determine the toxicity, response, and survival rate of orally administered combination chemotherapy in patients with AIDS-related intermediateand high-grade non-Hodgkin's lymphoma. Secondary objectives included prospective quality-of-life assessment and quantitation of cell-associated p24 antigen (p24 Ag) by flow cytometry. Patients and Methods: Eighteen patients with biopsy-proven lymphoma were treated with oral chemotherapy consisting of lomustine (CCNU) 100 mg/m2 on day 1, etoposide 200 mg/m2 on days 1 through 3; cyclophosphamide 100 mg/m2 on days 22 through 31, and procarbazine 100 mg/m2 on days 22 through 31 at 6-week intervals. A variety of clinical assessments were performed: prospective quality-of-life assessment using the Functional Living Index-Cancer (FLIC) and Brief Symptom Inventory (BSI) instruments; indirect immunofluorescence with flow cytometry to measure cell-associated p24 antigen; and price of the oral regimen compared with two other intravenous combination chemotherapy regimens. Results: The overall objective response rate using Eastern Cooperative Oncology Group (ECOG) criteria was 61 % (95% confidence interval, 39% to 84%), with seven complete remissions (39%) and four partial remissions (22%). The median survival duration was 7 months, with a range of 11 days to 36 months. The treatment-related mortality rate was 11 %. One patient developed CNS progression. Myelosuppression was the most frequent and severe toxicity encountered. Predictor variables of performance status (PS), prior history of thrush, and CD4 lymphocyte count were found to be of prognostic value. In a separate analysis, scores on the three subscales of the BSI were also found to be predictive of complete response. The price of this regimen is several thousand dollars less than that of other intravenous combination chemotherapy regimens. Conclusion: This regimen is active in patients with AIDS-related non-Hodgkin's lymphoma. Because it is important to design systemic cytotoxic chemotherapy regimens that are cost-effective, considerate of quality-of-life issues, and efficacious in this patient population, this approach should be compared with standard intravenous combination chemotherapy regimens in randomized controlled clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0027280130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027280130&partnerID=8YFLogxK

U2 - 10.1200/JCO.1993.11.9.1691

DO - 10.1200/JCO.1993.11.9.1691

M3 - Article

C2 - 8355036

AN - SCOPUS:0027280130

VL - 11

SP - 1691

EP - 1702

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -